ERBB2 and breast carcinoma: As expected, the combination of trastuzumab and docetaxel resulted in significant growth inhibition only in HER2+ breast cancer cells, whereas no effect of trastuzumab, either alone or combined with docetaxel, was observed in HER2-negative cells (Figure 2A).